Clinical trials
Idiopathic Pulmonary Fibrosis clinical trials
Below are recruiting idiopathic pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 85 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07082842RecruitingPhase 3
Testing HEC585 tablets for idiopathic pulmonary fibrosis
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
Beijing, Beijing MunicipalityAges 40–80 - NCT07174102Recruiting
Looking at lung scans in rheumatoid arthritis and related diseases
This trial studies lung scans (HRCT) from patients with rheumatoid arthritis, interstitial lung disease, or connective tissue disease to better understand lung involvement. If you have one of these conditions and have had a lung CT, you may be able to help.
PragueAges 18 years+ - NCT07482917Recruiting
Streamlining the diagnosis of interstitial lung disease
This study is testing a new way to speed up the diagnosis of interstitial lung disease (a group of lung scarring conditions). If you have symptoms or scan findings that suggest ILD but haven't been fully diagnosed yet, this trial may help you get a faster, clearer answer.
Granollers, BarcelonaAges 18 years+ - NCT00470327Recruiting
Study of how interstitial lung disease naturally changes
This study looks at how interstitial lung disease (lung scarring) typically progresses over time. It may help researchers understand what to expect and what changes to watch for.
Chicago, IllinoisAges 18 years+ - NCT07407543RecruitingPhase 1
Study of SRN001 in healthy Korean and Caucasian men
This trial tests a new drug called SRN001 in healthy men to see how safe it is and how the body processes it. It may help find the right dose for future studies.
SeoulAges 19–60 - NCT07454291RecruitingPhase 1
How taladegib works in healthy volunteers
This trial is for healthy volunteers to see how the study drug taladegib (ENV-101) interacts with other medicines in the body. It will help researchers understand how the drug is absorbed and processed, which is important for future studies in patients.
Brisbane, QueenslandAges 26–65 - NCT07652658RecruitingPhase 2
Study of AZD8965 for people with IPF
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
Birmingham, AlabamaAges 40 years+ - NCT07457463Recruiting
Pulmonary fibrosis self-management program
This study tests a learning and self-management program for people with pulmonary fibrosis. It helps you better understand and manage your lung condition.
BernAges 18 years+ - NCT07236541Recruiting
Mucus plugs and lung scarring in COPD patients having lung cancer surgery
This study looks at whether mucus plugs (thick mucus blocking the airways) in people with COPD might lead to more lung scarring after lung cancer surgery. It compares lung tissue from people with COPD to those with normal lungs.
ShanghaiAges 18–89 - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05895409Recruiting
Study risk factors in progressive lung scarring
This study looks at what factors contribute to worsening lung scarring seen on scans in people with certain lung diseases. Results may help doctors better understand and predict who will worsen over time.
Jinan, ShandongAges 18–80 - NCT06940427RecruitingPhase 2
Testing a new PET scan for lung scarring
This trial is testing a new type of PET scan (FAPI PET) to help doctors see if lung scarring (fibrosis) is getting worse or getting better. It may help decide if a treatment change is needed.
Madison, WisconsinAges 18 years+ - NCT07333183RecruitingPhase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Kissimmee, FloridaAges 18–85
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idiopathic pulmonary fibrosis?
- Yes. Clin2 currently lists 85 recruiting idiopathic pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.